Addex Therapeutics Ltd.
ADXN$8M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaGENEVA2 employees
Drugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Jun 30, 2026
10dMarket Overview
Stock performance and key metrics
ADXN News
Catalyst Timeline
1 upcoming, 1 past
Phase 1Next
Phase 1 — NTX-253
Jun 30, 2026AI-detected
For Schizophrenia. Neurosterix, an Addex spin-out company, is on track to complete its Phase 1 clinical study of NTX-253 for schizophrenia in Q2 2026. The study advancement represents routine clinical trial progress for the investigational psychiatric drug.
SourceDrug Pipeline
ADX10059
Gastroesophageal Reflux
ADX48621
Parkinson's Disease
Dipraglurant
Blepharospasm
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ADX10059 | Phase 2 | Gastroesophageal Reflux | - | - |
ADX48621 | Phase 2 | Parkinson's Disease | - | - |
Dipraglurant | Phase 2 | Blepharospasm | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply